Diggory P, Heyworth P, Chau G, McKenzie S, Sharma A, Luke I
Department of Geriatric Medicine, St. George's Hospital, London, UK.
Eye (Lond). 1993;7 ( Pt 5):661-3. doi: 10.1038/eye.1993.151.
Fifty-two elderly glaucomatous patients, without a history of asthma or obstructive airways disease, who were using topical timolol for control of intraocular pressure were recruited. Their topical therapy was changed to either betaxolol or pilocarpine. The change was associated with improvement in mean peak flow from 278 l/min to 328 l/min (t = 5.73, p < 0.001), mean FEV1 from 1.66 l to 1.85 l (t = 7.09, p < 0.001) and mean FVC from 2.40 l to 2.64 l (t = 5.07, p < 0.001). Change to either betaxolol or pilocarpine was associated with improved lung function tests. Lung function tests in a control group of 20 showed no significant changes. Both drugs maintained control of intraocular pressure but betaxolol had fewer ocular side effects.
招募了52名老年青光眼患者，他们没有哮喘或阻塞性气道疾病史，正在使用局部噻吗洛尔来控制眼压。他们的局部治疗改为倍他洛尔或毛果芸香碱。这种改变伴随着平均峰值流量从278升/分钟提高到328升/分钟（t = 5.73，p < 0.001），平均第一秒用力呼气容积从1.66升提高到1.85升（t = 7.09，p < 0.001），平均用力肺活量从2.40升提高到2.64升（t = 5.07，p < 0.001）。改为倍他洛尔或毛果芸香碱均与肺功能测试改善相关。20名对照组患者的肺功能测试无显著变化。两种药物均能维持眼压控制，但倍他洛尔的眼部副作用较少。
